Dabigatran

Click on "►" to expand: [−] Antithrombotics [×] Direct factor Xa inhibitors ► Direct thrombin inhibitors ► Heparins ► Platelet aggregation inhibitors ► Vitamin K antagonists   Abciximab   Acenocoumarol   Acetylsalicylic acid   Bivalirudin   Cilostazol   Clopidogrel   Dabigatran   Dalteparin   Dipyridamole/Acetylsalicylic acid   Enoxaparin   Prasugrel   Reviparin   Tenecteplase   Ticagrelor   Ticlopidine   Warfarin

BRAND NAMES

• International: Pradaxa
• Japan: Prazaxa
• U.S.: Pradaxa

STRUCTURE

INDICATIONS

Dabigatran is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (FDA)

DOSAGE

• For patients with CrCl >30 mL/min: 150 mg orally, twice daily.
• For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily

CONTRAINDICATIONS

• Active pathological bleeding
• History of serious hypersensitivity reaction to Dabigatran
• Mechanical prosthetic heart valve

WARNINGS AND PRECAUTIONS

• Risk of bleeding: Dabigatran can cause serious and, sometimes, fatal bleeding. Promptly evaluate signs and symptoms of blood loss.
• Bioprosthetic heart valves: Dabigatran use not recommended

SIDE EFFECTS

Most common adverse reactions (>15%) are gastritis-like symptoms and bleeding